Latest LLYC news and sentiment

Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

The battle between Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has so far been defined by blockbuster injectable weight loss drugs. But the next phase of that rivalry may look very different. Instead of competing over weekly injections, both companies are now racing to establish themselves in what could become the next major opportunity in obesity treatment: oral GLP-1 medicines. Eli Lilly (NYSE:LLY) has just taken an important step in that race with its once-daily drug Foundayo that targets the GLP-1 hormone. Britain's Medicines and Healthcare products Regulatory Agency (MHRA) approved F

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

Research collaboration combines Amplitude's proprietary taRNA with Lilly's global development, manufacturing, and commercialization capabilities Initial programs target infectious diseases with high unmet need, with Lilly retaining options for up to two additional targets BOSTON, Aug. 19, 2026 /PRNewswire/ -- Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company ("Lilly") to discover and develop taRNA vaccine candidates for infectious d

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

Quick Read AKTS retains full worldwide rights to its alpha-emitting cancer platform, with $517M cash and binary Q1 2027 trial data looming. NVS, whose Pluvicto grew 43% in Q2 2026, and LLY, already a $60M upfront partner, rank as the top two strategic acquirers. Analysts target $34 for AKTS while the 247 Wall St. base case reaches $42, but a failed readout erases the takeout premium entirely. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AKTS didn't make the cut. Grab the names FREE today. Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026,

Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs. Continue Reading

Why Eli Lilly (LLY) Stock Is Up Today

Why Eli Lilly (LLY) Stock Is Up Today What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program. According to a company press release, Eli Lilly acquired global rights to AlzeCure Pharma's Alzheimer's drug candidate, ACD680, for an upfront payment of $10 million. In addition, the agreement could exceed $1 billion in total value through future development and commercial milestone payments, plus mid-

Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli

Eli Lilly, Stock Of The Day, Is Erasing Novo's Early Lead In Weight-Loss Pills

Eli Lilly is Tuesday's IBD Stock Of The Day. Shares are staring down two potential entries as the weight-loss kingpin gains on Novo Nordisk. Continue Reading

PUBLIC SAFETY NOTICE: UNAPPROVED AND ILLEGAL RETATRUTIDE PRODUCTS

TORONTO, Aug. 17, 2026 /CNW/ -- Lilly Canada is warning the public about unapproved and illegal retatrutide sold on the black market, and detailing steps being taken to protect Canadians.Lilly Canada logo Retatrutide is an investigational molecule in Phase 3 clinical trials for obesity, type 2 diabetes, and other related indications. Retatrutide has not yet been approved for human use by Health Canada or any other regulatory agency in the world. It cannot be lawfully sold to consumers in Canada or elsewhere. Despite this, a black market for unapproved and illegal retatrutide exists globally. I

Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia

Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated Financing advances LTX-001 through initial readout from Phase 1b/2a trial and progresses LTX-002 through additional dosing cohorts of ongoing Phase 1/2 trial in ALS WORCESTER, Mass., Aug. 17, 2026 /PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A financing. The round includes new investor Eli Lilly and Company (Lilly), in addition t

Eli Lilly’s Weight-Loss Pill Just Got Its First Foothold in Europe

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose weight-loss franchise has become the single most important driver of its market value. Small-Molecule Flexibility The UK's Medicines and Healthcare Products Regulatory Agency approved orforglipron, offered under the brand name Foundayo, for weight los

Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth

On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for "agentic commercial," Veeva's AI-driven commercial framework designed to modernize field engagement and speed medicine delivery. While Veeva serves as the tech engine driving efficiency in life sciences, Eli Lilly stands as the pharmaceutical titan creating those therapies. Both occupy distinct sectors, enterprise software versus biopharmaceuticals, yet their expanding partnership highlights how technology

Eli Lilly (LLY) Steps Up Legal Fight Over Illegal Retatrutide Sales

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE: LLY) has intensified legal action against U.S. entities accused of selling unauthorized versions of its experimental obesity drug retatrutide. The company is pursuing multiple lawsuits as part of a broader effort to curb black market distribution of the unapproved treatment. Eli Lilly is also engaging regulators and online platforms to address patient safety risks and protect its obesity drug portfolio. This

Eli Lilly and Company (LLY) stock price, news, quote and history

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi

Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo